Advances in the formulations of non-injection administration of docetaxel

Journal of Drug Targeting

Volumn 22, Issue 2, 2014, Pages 87-94

  Zhang, Haiqun ^a   Dou, Jinfeng ^a   Zhai, Yingjie ^a   Liu, Anchang ^b   Zhai, Guangxi ^a  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

Docetaxel; Liposomes; Nanoparticles; Non injection administration

Indexed keywords

CYTOCHROME P450 3A4; DOCETAXEL; LIPOSOME; MULTIDRUG RESISTANCE PROTEIN; NANOCAPSULE; NANOPARTICLE;

CLINICAL PRACTICE; DISPERSION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG METABOLISM; DRUG SOLUBILITY; DRY POWDER INHALER; HUMAN; LIPOSOMAL DELIVERY; LUNG; MAXIMUM PLASMA CONCENTRATION; MICROEMULSION; MUCOADHESION; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; REVIEW; SOLID; SOLID DISPERSION;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; DRUG ADMINISTRATION ROUTES; DRUG DELIVERY SYSTEMS; HUMANS; SOLUBILITY; TAXOIDS;

EID: 84891749266     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2013.839686     Document Type: Review

References (62)

1. Walker RA, Jones JL, Chappell S, et al. Molecular pathology of breast cancer and its application to clinical management. Cancer Metast Rev 1997;16:5-27.
2. Figgitt DP, Wiseman LR. Docetaxel. Drugs 2000;59:621-51.
3. Kaye SB. The integration of docetaxel into first-line chemotherapy for ovarian cancer. Int J Gynecol Cancer 2001;11:31-3.
4. Belani CP, Eckardt J. Development of docetaxel in advanced nonsmall-cell lung cancer. Lung Canc 2004;46:3-11.
5. Petrylak DP. Docetaxel (Taxotere) in hormone-refractory prostate cancer. Semin Oncol 2000;27:24-9.
6. Ridwelski K, Gebauer T, Fahlke J, et al. Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer. Ann Oncol 2001;12:47-51.
7. Lavelle F, Bissery MC, Combeau C, et al. Preclinical evaluation of docetaxel (Taxotere). Semin Oncol 1995;22:3-16.
8. Cortes JE, Pazdur R. Docetaxel. J Clin Oncol 1995;13:2643-55.
9. Diaz JF, Andreu JM. Assembly of purified GDP-tubulin into microtubules induced by Taxol and Taxotere: reversibility, ligand stoichiometry, and competition. Biochemistry 1993;32:2747-55.
10. Riou JF, Petitgenet O, Combeau C, Lavelle F. Cellular uptake and efflux of docetaxel (Taxotere) and paclitaxel (Taxol) in P388 cell line. Proc Am Assoc Cancer Res 1994;35:385.
11. Haldar S, Basu A, Croce CM. Bcl2 is the guardian of microtubule integrity. Cancer Res 1997;57:229-33.
12. Haas H. Development of new taxane formulations. Pharm Unserer Zeit 2005;34:115-21.
13. Baker J, Ajani J, Scotte F, et al. Docetaxel-related side effects and their management. Eur J Oncol Nurs 2009;13:49-59.
14. Feng SS, Chien S. Chemotherapeutic engineering: application and further development of chemical engineering principles for chemotherapy of cancer and other diseases. Chem Eng Sci 2003;58: 4087-114.
15. Aisner J. Overview of the changing paradigm in cancer treatment: oral chemotherapy. Am J Health Syst Pharm 2007;64:4-7.
16. Gao K, Sun J, Liu K, et al. Preparation and characterization of a submicron lipid emulsion of docetaxel: submicron lipid emulsion of docetaxel. Drug Dev Ind Pharm 2008;34:1227-37.
17. Park K. Nanovehicles for enhanced oral delivery of taxanes. J Contr Rel 2009;140:77-8.
18. Waterschoot RA, Lagas JS, Wagenaar E, et al. Absence of both cytochromeP4503A and P-glycoprotein dramatically increases docetaxel oral bioavailability and risk of intestinal toxicity. J Cancer Res Clin 2009;69:8996-9002.
19. Sun P, Zhang Y, Shi L, Gan Z. Thermosensitive nanoparticles selfassembled from PCL-b-PEO-b-PNIPAAm triblock copolymers and their potential for controlled drug release. Macromol Biosci 2010; 10:621-31.
20. Hobbs SK, Monsky WL, Yuan F, et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci USA 1998;95:4607-12.
21. Sanders E, Ashworth CT. A study of particulate intestinal absorption and hepatocellular uptake. Exp Cell Res 1961;22: 137-45.
22. Florence AT, Hillery AM, Hussain N, Jani PU. Nanoparticles as carriers for oral peptide absorption: studies on particle uptake and fate. J Control Release 1995;36:39-46.
23. Lefevre ME, Vanderhoff JW, Laussue JA, Joel DD. Accumulation of 2-mm latex particles in mouse Peyer's patches during chronic latex feeding. Cell Mol Life Sci 1978;34:120-2.
24. Jung T, Kamm W, Breitenbach A, et al. Biodegradable nanoparticles for oral delivery of peptides: is there a role for polymers to affect mucosal uptake? Eur J Pharm Biopharm 2000;50:147-60.
25. Delie F. Evaluation of nano-and microparticle uptake by the gastrointestinal tract. Adv Drug Del Rev 1998;34:221-33.
26. Mu L, Feng SS. A novel controlled release formulation for anticancer drug paclitaxel (Taxols): PLGA nanoparticles containing vitamin E TPGS. J Contr Rel 2003;86:33-48.
27. Mu L, Feng SS. PLGA/TPGS nanoparticles for controlled release of paclitaxel: effects of the emulsifier and the drug loading ratio. Pharm Res 2003;20:1864-72.
28. Feng SS, Mei L, Anitha P, et al. Poly(lactide)-vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of Docetaxel. Biomaterials 2009;30:3297-306.
29. Lee YH, Kuo TF, Chen BY, et al. Toxicity assessment of montmorillonite as a drug carrier for pharmaceutical applications: yeast and rats model. Biomed Eng-App Bas C 2005;17:12-18.
30. Norris DA, Puri N, Sinko PJ. The effect of physical barriers and properties on the oral absorption of particulates. Adv Drug Del Rev 1998;34:135-54.
31. Kawakami K, Yoshikawa T, Moroto Y, et al. Microemulsion formulation for enhanced absorption of poorly soluble drugs prescription design. J Control Rel 2002;81:65-74.
32. Araya H, Tomita M, Hayashi M. The novel formulation design of O/W microemulsion for improving the gastrointestinal absorption of poorly water soluble compounds. Int J Pharm 2005;305:61-74.
33. Kawakami K, Yoshikawa T, Hayashi H, et al. Microemulsion formulation for enhanced absorption of poorly soluble drugs II. In vivo study. J Contr Rel 2002;81:75-82.
34. Shah NH, Carvajal MT, Patel CI, et al. Self-emulsifying drug delivery systems (SEDDS) with polyglycolyzed glycerides for improving in vitro dissolution and oral absorption of lipophilic drugs. Int J Pharm 1994;106:15-23.
35. Constantinides PP. Lipid microemulsions for improving drug dissolution and oral absorption: physical and biopharmaceutical aspects. Pharm Res 1995;12:156-72.
36. Yin YM, Cui FD, Mu CF, et al. Docetaxel microemulsion for enhanced oral bioavailability: preparation and in vitro and in vivo evaluation. J Contr Rel 2009;140:86-94.
37. Leuner C, Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm 2000;50:47-60.
38. Serajuddin ATM. Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. J Pharm Sci 1999;88:1058-66.
39. Moes JJ, Koolen SLW, Huitema ADR, et al. Pharmaceutical development and preliminary clinical testing of an oral solid dispersion formulation of docetaxel (ModraDoc001). Int J Pharm 2011;420:244-50.
40. Kruijtzer CM, Beijnen JH, Schellens JH. Improvement of oral drug treatment by temporary inhibition of drug transporters and/or Cytochrome P450 in the gastrointestinal tract and liver: an overview. Oncologist 2002;7:516-30.
41. Kean T, Thanou M. Biodegradation, biodistribution and toxicity of chitosan. Adv Drug Del Rev 2010;62:3-11.
42. Lee E, Kim H, Lee IH, Jon S. In vivo antitumor effects of chitosanconjugated docetaxel after oral administration. J Contr Rel 2009; 140:79-85.
43. Khatun Z, Nurunnabi M, Reeck GR, et al. Oral delivery of taurocholic acid linked heparin-docetaxel conjugates for cancer therapy. J Control Release 2013;170:74-82.
44. Park K, Lee GY, Kim YS, et al. Heparin-deoxycholic acid chemical conjugate as an anticancer drug carrier and its antitumor activity. J Contr Rel 2006;114:300-6.
45. Kim SK, Lee DY, Lee E, et al. Absorption study of deoxycholic acid-heparin conjugate as a new form of oral anti-coagulant. J Control Release 2007;120:4-10.
46. Nurunnabi M, Khatun Z, Moon WC, et al. Heparin based nanoparticles for cancer targeting and noninvasive imaging. Quant Imaging Med Surg 2012;2:219-26.
47. Nassar T, Qadri SA, Frenkel OH, et al. High plasma levels and effective lymphatic uptake of docetaxel in an orally available nanotransporter formulation. Cancer Res 2011;71: 3018-28.
48. Naik A, Kalia YN, Guy RH. Transdermal drug delivery: overcoming the skin's barrier function. Pharm Sci Technolo Today 2000;3:318-26.
49. Elsayed MMA, Abdallah OY, Naggar VF, Khalafallah NM. Lipid vesicles for skin delivery of drugs: reviewing three decades of research. Int J Pharm 2007;332:1-16.
50. Cevc G, Blume G. Lipid vesicles penetrate into intact skin owing to the transdermal osmotic gradients and hydration force. Biochim Biophys Acta 1992;1104:226-32.
51. Mishra D, Garg M, Dubey V, et al. Elastic liposomes mediated transdermal delivery of an anti-hypertensive agent: propranolol hydrochloride. J Pharm Sci 2007;96:145-55.
52. Qiu YQ, Gao YH, Hu KJ, Li F. Enhancement of skin permeation of docetaxel: a novel approach combining microneedle and elastic liposomes. J Contr Rel 2008;129:144-50.
53. Qiu YQ, Li S, Li F, et al. Enhancement of transdermal delivery of docetaxel by surfactantethanolic liposomes. J Chin Pharm Sci 2011; 20:466-72.
54. Saad M, Garbuzenko OB, Minko T. Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer. Int J Nanomed 2008;3:761-76.
55. Timothy M, Crowder TM, Rosati JA, et al. Fundamental effects of particle morphology on lung delivery: predictions of Stokes' Law and the particular relevance to dry powder inhaler formulation and development. Pharm Res 2000;19:239-45.
56. Telko MJ, Hickey AJ. Dry powder inhaler formulation. Resp Care 2005;50:1209-27.
57. Islam N, Gladki E. Dry powder inhalers (DPIs)-a review of device reliability and innovation. Int J Pharm 2008;360:1-11.
58. Jinturkar KA, Anish C, Kumar MK, et al. Liposomal formulations of Etoposide and Docetaxel for p53 mediated enhanced cytotoxicity in lung cancer cell lines. Biomaterials 2012;33: 2492-507.
59. Chiang LM, Wang HS, Shen HH, et al. Rectal diazepam solution is as good as rectal administration of intravenous diazepam in the first-aid cessation of seizures in children with intractable epilepsy. Pediatr Neonatol 2011;52:30-3.
60. Hoogdalem E, de Boer AG, Breimer DD. Pharmacokinetics of rectal drug administration, Part I. Clin Pharmacokinet 1991;21: 11-26.
61. Yuan Y, Cui Y, Zhang L, et al. Thermosensitive and mucoadhesive in situ gel based on poloxamer as new carrier for rectal administration of nimesulide. Int J Pharm 2012;430:114-19.
62. Choi HG, Yong CS, Yeo WH. Docetaxel-loaded thermosensitive liquid suppository composition for rectal administration. WIPO, 2011. Available from: http://patentscope.wipo.int/search/en/detail. jsf?docId=WO2011129627&recNum= 191&docAn=KR20110026 62&queryString=evaporators&maxRec=179088 [last accessed 20 Oct 2011].